Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2-treated patients.
Hartmann
L C
LC
Division of Cancer Treatment, National Cancer Institute, Frederick, MD 21701.
Urba
W J
WJ
Steis
R G
RG
Smith
J W
JW
Vander Molen
L A
LA
Creekmore
S P
SP
Sznol
M
M
Casciano
M A
MA
Engler
N
N
Longo
D L
DL
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002405:Catheterization, Central Venous / Q000009:adverse effects; D002408:Catheters, Indwelling / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D011446:Prospective Studies; D018805:Sepsis / Q000209:etiology / Q000517:prevention & control*
D000900:Anti-Bacterial Agents; D007376:Interleukin-2